Prediction Case File
YouTubeTracking Live

I’m BUYING NIKE Stock! Here’s Exactly When:

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
02 Oct 2026, 13:35 UTC
Recorded by Tahlil Plus
02 Oct 2026, 16:23 UTC
Video preview for I’m BUYING NIKE Stock! Here’s Exactly When:
Source overview

AI-generated source summary

The video discusses Nike's (NKE) recent earnings report, highlighting a significant year-to-date decline and weakness in its China sales. While earnings per share beat expectations (48 cents vs. 43 cents), revenue fell slightly short ($11.21 billion vs. $11.32 billion expected). A key concern is the declining revenue in Greater China, which has seen a significant percentage decrease over the past quarters, contrasting with the overall market growth in China's sportswear sector. Competitors like Adidas are reportedly growing in China, suggesting Nike is losing market share. The company is undergoing a restructuring plan called 'Pace' to improve efficiency, involving layoffs and a projected $2.5 billion in savings by fiscal 2031, with a 15-cent per share restructuring expense in fiscal 2027. Fundamental analysis suggests a forward P/E ratio of around 20x, significantly lower than historical averages. The dividend yield is currently around 4.1%, with free cash flow covering it, but buybacks have ceased. Given the declining EPS and net income margin forecasts, the analysis suggests a target price of $26.50, with a failure bound at $53.00.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
360
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail